EUCTR2004-000585-13-CZ进行中（未招募）不适用
A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6–59 Months of Age
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 8,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Age 6 through 59 months of age (not reached their 5th year birthday at the time of randomization); (2) Parent/guardian available by telephone; (3) Available for illness visits at clinic or at home during the influenza surveillance period; (4) Written informed consent (and HIPAA authorization for US participants) obtained from the participant’s parent or legal guardian; and (5) Ability of the parent/guardian to understand and comply with the requirements of the protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) History of hypersensitivity to any component of CAIV-T or inactivated influenza vaccine, including egg or egg protein (2) History of hypersensitivity to gentamicin (3) Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy; (4) History of Guillain-Barre syndrome; (5) Medically-diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled) within the previous 42 days by parent report or chart review (e.g. children with recent persistent asthma are excluded), or history of severe asthma; (6) Acute febrile (greater than 100.0 degrees Fahrenheit or greater than 37.8 degrees Celsius oral or equivalent) illness or acute respiratory illness, including cough or sore throat, within three days prior to enrollment; (7) Receipt of an investigational product within 30 days prior to enrollment or expected receipt during this study; (8) Use of aspirin or salicylate-containing products 30 days prior to enrollment or expected receipt during this study; (9) Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanazmivir) within 14 days prior to enrollment or expected receipt during this study; (10) Receipt of any blood product within 90 days prior to vaccination or expected receipt during this study; (11) Administration of any live virus vaccine within 30 days prior to enrollment, or if receipt of another live virus vaccine is expected within 30 days of any study vaccination; (12) Administration of any inactivated vaccine within 14 days prior to enrollment or if receipt of another inactivated vaccine is expected within 14 days of any study vaccination; (13) Close contact who is severely immunocompromised (e.g. transplant recipient); (14) Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study; and (15) Any condition that, in the opinion of the investigator, might interfere with the interpretation or evaluationof the vaccines.
- •Note: An individual who initially is excluded from study participation based on one or more of the above time-limited criteria (e.g., acute febrile or acute respiratory illness, etc.) may be reconsidered for enrollment once the condition has resolved. Similarly, in cases of short term, reversible conditions, such as acute febrile or respiratory illness, Dose Two should be deferred until the child has recovered. Also, for children who experienced medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled) within 42 days post Dose One, Dose Two should be deferred until a 42 day wheeze-free and bronchodilator/steroid-free period has elapsed. For children who have received another vaccine or anti-influenza medication in the intervening period, Dose Two should be deferred until the requisite period (14 days for inactivated vaccines and for anti-influenza medications, and 30 days for live vaccines) has elapsed. Subjects will not be permitted to receive their Dose Two medication if it is deferred past January 15, 2005.
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82